China's national generics procurement cuts prices up to 93%

22 January 2020

By Wang Fangqing

The second round of China’s national generics procurement, which ended on January 17, saw 53% price cuts on average of the 32 drugs that treat diseases including cancer and type II diabetes.

While most suppliers are Chinese companies, the list also includes four foreign drug suppliers – Bayer (BAYN: DE), Celgene, which is now part of Bristol-Myers Squibb (NYSE: BMY), Novartis (NOVN: VX) unit Sandoz and Boehringer Ingelheim. Bayer will be the supplier for moxifloxacin (trade name Avelox) tablets and acarbose (trade name Glucobay) tablets; Celgene for paclitaxel (trade name (Abraxane) injection; Sandoz for simvastatin (trade name Zocor) tablets and BI will supply meloxicam (trade name Mobic) tablets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK